3 reasons to hold on to your CSL Limited shares

There's no doubt CSL Limited is expensive, but long-term holders are still likely to reap rewards.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Protein science and blood plasma company CSL Limited (ASX: CSL) has been pretty flat over the last six months (up less than 2%), and it yields only 1.6%, so it's understandable that some Australian investors (who love their dividends) might be hesitant to hold. However, investors throughout the world see the value in this stock – here are three reasons why it deserves a spot in your portfolio.

1) Return on investment (ROI) has been steadily growing for 10 years. This is rare for a blue-chip superstar stock. For example, biotech company Cochlear Limited (ASX: COH) has had fairly flat ROI over the last 10 years, and mining companies tend to see their ROI fluctuate with commodity cycles.

2) Dividends have grown consistently over the last decade, with a compound annual growth rate (CAGR) of 27.3% since 2004. However the CAGR from 2010 – 2014 is just 11.2%, which I believe is more indicative for the coming decade (another decade of 27.3% dividend growth is a ludicrous suggestion, in my opinion.) However, I think 10% growth is reasonably likely, as the company continues to buy back shares.

3) The ageing population in developed nations will drive demand for CSL's products. For example, the company's new drug, Kcentra, is designed to treat people (undergoing surgery) who are on the drug Warfarin. Warfarin is an anti-coagulant used to reduce the risk of heart attack, and it is generally administered to people as they age. The more people who are on Warfarin, the more demand there will be for Kcentra.

Over the long term, I believe that an investment in CSL will probably beat the market. The company is considered one of the safest stocks, but I do fear it is a bit too expensive at the moment. Generally, it is better to buy shares in a company that is slightly out of favour. For example, I suggested readers buy shares in ResMed Inc. (CHESS) (ASX: RMD) after they released some disappointing results, and I would do the same if CSL temporarily disappointed the market. It's also worth keeping in mind that were you to buy CSL at a better price, then the dividend yield would be more attractive.

Motley Fool contributor Claude Walker (@claudedwalker) does not own shares in any of the companies mentioned in this article.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »